A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
The results of this study are not yet available.
The study will last about 8 months and may include up to 9 visits.
Here you can find out a bit more about the requirements for volunteers who took part in this study
• Participants must have a diagnosis of migraine or chronic migraine • Participants must have a history of migraine headaches at least 1 year prior to screening, with onset prior to age 50 • Participants must have failed previous migraine preventive medications in the past 10 years due to inadequate efficacy or tolerability • Participants must not be currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product • Participants must not currently use or have prior exposure to galcanezumab or another CGRP antibody • Participants must not have a history of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) • Participants must not be pregnant or nursing